Security record · archived quarter
LXRX
Lexicon Pharmaceuticals, Inc. · Healthcare · Biotechnology
8Tracked holders
0Δ holders
7.88MShares held
$12.37MReported value
+0New positions
−0Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -30.0% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +16 | 115.42M | $276.97M | +20 | −4 |
| Q1 2026 | 53 | +1 | 96.42M | $150.42M | +5 | −4 |
| Q4 2025 | 51 | +1 | 73.64M | $84.69M | +2 | −1 |
| Q3 2025 | 13 | 0 | 62.78M | $84.76M | +2 | −2 |
| Q2 2025 | 10 | +2 | 57.50M | $54.38M | +4 | −2 |
| Q1 2025 | 5 | -2 | 7.56M | $3.49M | +1 | −3 |
| Q4 2024 | 7 | -2 | 16.13M | $11.91M | +1 | −3 |
| Q3 2024 | 8 | 0 | 7.88M | $12.37M | — | — |
| Q2 2024 | 8 | — | 12.44M | $20.91M | — | — |
Who holds it · Q3 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 3.52M | +8.4% | $5.53M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 1.40M | +134.2% | $2.20M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Point72 Asset Management ✦ | 1.23M | -70.2% | $1.93M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 732.75K | -0.8% | $1.15M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 574.15K | -51.8% | $901,416 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 204.88K | +969.5% | $321,660 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 117.18K | 0.0% | $184,000 | 0.0% | Held | 2 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 98.62K | -95.9% | $154,840 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 136 holders, 323.38M shares, $502.11M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2024 ·
Methodology ·
Get this via the API